CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The gene for chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) was recently identified as a target oncogene within the 1q21 amplicon, which occurs in 46% to 86% of primary hepatocellular carcinoma (HCC) cases. However, the prognostic significance of CHD1L in HCC remains uncertain. In this study, we investigated the roles of CHD1L in the prognosis of HCC. Methods: We investigated the expressions of CHD1L in tumor tissue microarrays of 281 primary HCC patients who underwent surgical resection using immunohistochemistry. Prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 75.6 months. Results: CHD1L expression was observed in 48 of the 281 HCCs (17.1%). CHD1L expression was associated with a younger age (p=0.033), higher Edmondson grade (p=0.019), microvascular invasion (p<0.001), major portal vein invasion (p=0.037), higher American Joint Committee on Cancer T stage (p=0.001), lower albumin level (p=0.047), and higher α-fetoprotein level (p=0.002). Multivariate analyses revealed that CHD1L expression (p=0.027), Edmondson grade III (p=0.034), and higher Barcelona Clinic Liver Cancer stage (p< 0.001) were independent predictors of shorter disease-free survival. Conclusions: CHD1L expression might be a prognostic marker of shorter disease-free survival in HCC patients after surgical resection.
Abstract
Background: The gene for chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) was recently identified as a target oncogene within the 1q21 amplicon, which occurs in 46% to 86% of primary hepatocellular carcinoma (HCC) cases. However, the prognostic significance of CHD1L in HCC remains uncertain. In this study, we investigated the roles of CHD1L in the prognosis of HCC. Methods: We investigated the expressions of CHD1L in tumor tissue microarrays of 281 primary HCC patients who underwent surgical resection using immunohistochemistry. Prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 75.6 months. Results: CHD1L expression was observed in 48 of the 281 HCCs (17.1%). CHD1L expression was associated with a younger age (p=0.033), higher Edmondson grade (p=0.019), microvascular invasion (p<0.001), major portal vein invasion (p=0.037), higher American Joint Committee on Cancer T stage (p=0.001), lower albumin level (p=0.047), and higher α-fetoprotein level (p=0.002). Multivariate analyses revealed that CHD1L expression (p=0.027), Edmondson grade III (p=0.034), and higher Barcelona Clinic Liver Cancer stage (p< 0.001) were independent predictors of shorter disease-free survival. Conclusions: CHD1L expression might be a prognostic marker of shorter disease-free survival in HCC patients after surgical resection.
참고문헌 (23)
- Llovet JM, "Resection and liver transplantation for hepatocellular carcinoma", Semin Liver Dis, 25, pp.181~200 (2005)
- Poon RT, "Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge", Hepatology, 54, pp.757~759 (2011)
- Ho MC, "A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach", Ann Surg Oncol, 13, pp.1474~1484 (2006)
- Ma NF, "Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma", Hepatology, 47, pp.503~510 (2008)
- Sakakura C, "Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization", Br J Cancer, 80, pp.2034~2039 (1999)
- Chang J, "Assessment of chromosomal losses and gains in hepatocellular carcinoma", Cancer Lett, 182, pp.193~202 (2002)
- Flaus A, "Identification of multiple distinct Snf2 subfamilies with conserved structural motifs", Nucleic Acids Res, 34, pp.2887~2905 (2006)
- Eisen JA, "Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions", Nucleic Acids Res, 23, pp.2715~2723 (1995)
- Chen L, "CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients", J Clin Invest, 120, pp.1178~1191 (2010)
- Chen L, "Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion", Gut, 60, pp.534~543 (2011)
- Edmondson HA, "Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies", Cancer, 7, pp.462~503 (1954)
- Liver Cancer Study Group of Japan, "The general rules for the clinical and pathological study of primary liver cancer", pp.38~ (2003), Kanehara
- Edge SB, "Trotti A 3rd. AJCC cancer staging manual" (2010), Springer
- Llovet JM, "Prognosis of hepatocellular carcinoma: the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
- Hoshida Y, "Gene expression in fixed tissues and outcome in hepatocellular carcinoma", N Engl J Med, 359, pp.1995~2004 (2008)
- Terminology of nodular hepatocellular lesions, "International Working Party", Hepatology, 22, pp.983~993 (1995)
- Gao J, "Deregulated expression of Notch receptors in human hepatocellular carcinoma", Dig Liver Dis, 40, pp.114~121 (2008)
- Wong N, "Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis", Am J Pathol, 154, pp.37~43 (1999)
- Wong N, "Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression", J Hepatol, 38, pp.298~306 (2003)
- Chen M, "Transgenic CHD1L expression in mouse induces spontaneous tumors", PLoS One, 4, pp.e6727~ (2009)
- Miller G, "Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract", J Exp Clin Cancer Res, 28, pp.62~ (2009)
- Gümüs-Akay G, "DNA copy number changes in gastric adenocarcinomas: high resolution-comparative genomic hybridization study in Turkey", Arch Med Res, 40, pp.551~560 (2009)
- Tsuji K, "Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues", BMC Cancer, 10, pp.15~ (2010)